VivoSeq
Infectious Disease

Pneumonia

423

Pipeline Programs↗

65

Active Trials↗

126

Companies Involved↗

Pneumonia is a highly competitive landscape with 423 programs across 126 companies. The most active players are Airway Therapeutics, Inc., CAR-T (Shanghai) Biotechnology Co., Ltd., Cho Pharma Inc.. 79 therapies are approved with 128 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

92/100

Pipeline Velocity

51/100

Mech. Concentration

12/100

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Airway Therapeutics, Inc.

1 program

Phase 1C

CAR-T (Shanghai) Biotechnology Co., Ltd.

1 program

Phase 1C

Cho Pharma Inc.

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1M

Meitheal

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical96

Foscarnet Sodium

National Institute of Allergy and Infectious Diseases (NIAID)

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Imipenem

Pfizer

Famotidine

Kenvue Brands

Rabeprazole

Akero Therapeutics

Phase 124

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Ceftaroline

Pfizer

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Colchicine

Alnylam Pharmaceuticals

Active

Pfizer

Phase 296

Anakinra

Swedish Orphan Biovitrum

Ticagrelor

AstraZeneca

Melphalan

Apotex Inc.

Bevacizumab

Bio-Thera Solutions

Thalidomide

Bristol-Myers Squibb

Phase 3128

Cefuroxime

Philadelphia Eye Associates

Canakinumab

Novartis

Chlorhexidine Gluconate

Medline Industries

Baricitinib

Eli Lilly

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Approved79

Nitric Oxide

Mallinckrodt

Linezolid

Pfizer

Metoclopramide

Istituto Clinico Humanitas

Prednisolone Acetate

Novartis

Colistin

Parkedale

Analysis

Modality Breakdown

93%

Small molecule

464 of 497 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody143%Vaccine82%Cell therapy71%Protein / enzyme3<1%Peptide1<1%

Small molecule leads; the ring shows all 497 classified programs, each share of the total. Modality classified for 100% of 548 pipeline programs.

Analysis

Trial Status

575

clinical trials

Completed312 · 54%
Unknown status120 · 21%
Terminated48 · 8%
Recruiting35 · 6%
Withdrawn28 · 5%
Not yet recruiting25 · 4%
Other7 · 1%

Clinical Trials

Trial Activity

575 trials

Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05903352·328 enrolled
Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia
Recruiting·—·Phase 4·NCT07414693·90 enrolled
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
Recruiting·IInstituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo·N/A·NCT05354778·180 enrolled
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Recruiting·JJena University Hospital·Phase 3·NCT06134492·616 enrolled
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled
Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia
Recruiting·WWest China Second University Hospital·N/A·NCT06881056·90 enrolled
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
Recruiting·MMundipharma Research Limited·Phase 2·NCT05835479·50 enrolled
Effect of High Dose Intravenous Vitamin C in Severe Pneumonia
Recruiting·—·Phase 2·NCT05842382·484 enrolled
Study of the Efficacy and Safety of Antioxidants Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.
Recruiting·FFuture University in Egypt·Phase 4·NCT06334874·80 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses
Recruiting·RRuijin Hospital·Phase 1·NCT06693362·60 enrolled
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Recruiting·KKARE Biosciences·Phase 2/3·NCT05706454·324 enrolled
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Recruiting·BBiotest·Phase 3·NCT05722938·590 enrolled
Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
Recruiting·BBiomedica Foscama S.p.A. Industria Chimico-Farmaceutica·Phase 3·NCT06296212·178 enrolled
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Recruiting·VVasomune Therapeutics, Inc.·Phase 2·NCT05123755·120 enrolled
A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia
Recruiting·SShandong University·N/A·NCT06972537·42 enrolled
Page 1 of 39

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)